Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1026706 effect on LEP in UVB and capsaicin models
NCT02037165Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1026706 in pain (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser Evoked Potentials (LEP) in UVB-Irradiated Skin up to 24 hours. Started Jan 2014; status: completed.
02
Drugs
BI 1026706
03
Conditions
pain
Beyond the preview
Go deeper on NCT02037165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037165.